We are live on ! Find out more
CALA

Calithera Biosciences, Inc

Delisted

CALA was delisted on the 1st of February, 2023.

94 hedge funds and large institutions have $382M invested in Calithera Biosciences, Inc in 2017 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 35 increasing their positions, 13 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

169% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 13

124% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 17

69% more capital invested

Capital invested by funds: $226M → $382M (+$157M)

27% more funds holding

Funds holding: 7494 (+20)

60% less call options, than puts

Call options by funds: $1.22M | Put options by funds: $3.01M

Holders
94
Holders Change
+20
Holders Change %
+27.03%
% of All Funds
2.34%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
38
Increased
35
Reduced
13
Closed
17
Calls
$1.22M
Puts
$3.01M
Net Calls
-$1.8M
Net Calls Change
-$1.55M

CALA Hedge Fund Activity: Q2 2017 in Review

94 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Calithera Biosciences, Inc (CALA) for Q2 2017, worth a combined $382M — up 69% from $226M a quarter earlier.

Buyers outnumbered sellers: 38 funds opened new CALA positions and 17 closed out — a net gain of 21 holders — while 35 added to existing stakes and 13 trimmed.

The largest buyer was BlackRock, adding an estimated $23.5M. The largest seller was RA Capital Management, exiting entirely with an estimated $8.37M sold.

  • 94 institutional investors held Calithera Biosciences, Inc (CALA) as of Q2 2017, up from 74 in Q1 2017.
  • Funds reported $382M of Calithera Biosciences, Inc stock for Q2 2017, up 69% quarter-over-quarter.
  • 38 funds opened new Calithera Biosciences, Inc positions in Q2 2017 and 17 closed out, a net change of +21 holders.
  • The largest Calithera Biosciences, Inc buyer in Q2 2017 was BlackRock, an estimated $23.5M added.
  • The largest Calithera Biosciences, Inc seller in Q2 2017 was RA Capital Management, an estimated $8.37M sold.

Based on aggregated 13F filings for Q2 2017.